We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Zai Lab (ZLAB) Up on Breakthrough Therapy Tag for Oncology Drug
Read MoreHide Full Article
Zai Lab Limited’s (ZLAB - Free Report) shares were up more than 11% on Aug 30, as its pipeline candidate, repotrectinib, obtained Breakthrough Therapy designation from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China for treating patients with advanced solid tumors that have an NTRK gene fusion, who have progressed following treatment with tyrosine kinase inhibitors (TKIs).
The designation expedites the development and review of drugs for severe or life-threatening conditions for which there is no existing treatment, or where sufficient evidence indicates advantages of the novel drug over currently available treatment options.
The benefits include priority communications and guidance from the CDE to promote and expedite the drug development process.
ZLAB has an exclusive license agreement with Turning Point (acquired by Bristol Myers Squibb) to develop and commercialize repotrectinib in Greater China.
Zai Lab’s shares have lost 13.7% year to date compared with the industry's 11.8% decline.
Image Source: Zacks Investment Research
The Breakthrough Therapy tag is based on the global phase I/II TRIDENT-1 studywhere repotrectinib demonstrated high response rates and clinically meaningful durability of benefit in both TKI-naïve and TKI-pretreated patients.
Repotrectinib is a next-generation TKI that specifically targets ROS1 and NTRK oncogenic drivers implicated in advanced solid tumors, including non-small cell lung cancer (NSCLC).
In the United States, repotrectinib has already received three Breakthrough Therapy Designations from the FDA for various indications related to ROS1-positive metastatic NSCLC and advanced solid tumors with NTRK gene fusions.
In June 2023, the NMPA in China accepted a new drug application (NDA) seeking approval for repotrectinib to treat adult patients with locally advanced or metastatic ROS1-positive NSCLC. A similar NDA was also accepted by the FDA in the United States for the same indication in May 2023.
Zai Lab Limited Unsponsored ADR Price and Consensus
In the past 90 days, the Zacks Consensus Estimate forANI Pharmaceuticals’ earnings has gone up from $3.31 per share to $3.73 for 2023. The bottom-line estimate has increased from $4.32 to $4.35 for 2024 during the same time frame. Shares of the company have rallied 60.6% year to date.
ANIP’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 91.56%.
In the past 90 days, the Zacks Consensus Estimate for Annovis Bio has narrowed from a loss of $4.89 per share to a loss of $4.38 for 2023. The bottom-line estimate has narrowed from a loss of $3.18 to $2.77 for 2024 during the same time frame. Shares of the company have lost 7.9% year to date.
ANVS’ earnings beat estimates in three of the trailing four quarters and missed the mark in one, delivering an average surprise of 13.40%.
In the past 90 days, the Zacks Consensus Estimate for Corcept’s earnings has gone up from 62 cents per share to 78 cents for 2023. The bottom-line estimate has also improved from 61 cents to 83 cents for 2024 during the same time frame. Shares of the company have rallied 61.8% year to date.
CORT’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 6.99%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Zai Lab (ZLAB) Up on Breakthrough Therapy Tag for Oncology Drug
Zai Lab Limited’s (ZLAB - Free Report) shares were up more than 11% on Aug 30, as its pipeline candidate, repotrectinib, obtained Breakthrough Therapy designation from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China for treating patients with advanced solid tumors that have an NTRK gene fusion, who have progressed following treatment with tyrosine kinase inhibitors (TKIs).
The designation expedites the development and review of drugs for severe or life-threatening conditions for which there is no existing treatment, or where sufficient evidence indicates advantages of the novel drug over currently available treatment options.
The benefits include priority communications and guidance from the CDE to promote and expedite the drug development process.
ZLAB has an exclusive license agreement with Turning Point (acquired by Bristol Myers Squibb) to develop and commercialize repotrectinib in Greater China.
Zai Lab’s shares have lost 13.7% year to date compared with the industry's 11.8% decline.
Image Source: Zacks Investment Research
The Breakthrough Therapy tag is based on the global phase I/II TRIDENT-1 studywhere repotrectinib demonstrated high response rates and clinically meaningful durability of benefit in both TKI-naïve and TKI-pretreated patients.
Repotrectinib is a next-generation TKI that specifically targets ROS1 and NTRK oncogenic drivers implicated in advanced solid tumors, including non-small cell lung cancer (NSCLC).
In the United States, repotrectinib has already received three Breakthrough Therapy Designations from the FDA for various indications related to ROS1-positive metastatic NSCLC and advanced solid tumors with NTRK gene fusions.
In June 2023, the NMPA in China accepted a new drug application (NDA) seeking approval for repotrectinib to treat adult patients with locally advanced or metastatic ROS1-positive NSCLC. A similar NDA was also accepted by the FDA in the United States for the same indication in May 2023.
Zai Lab Limited Unsponsored ADR Price and Consensus
Zai Lab Limited Unsponsored ADR price-consensus-chart | Zai Lab Limited Unsponsored ADR Quote
Zacks Rank & Stocks to Consider
Zai Lab currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the same industry are ANI Pharmaceuticals (ANIP - Free Report) , Annovis Bio (ANVS - Free Report) and Corcept Therapeutics (CORT - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 90 days, the Zacks Consensus Estimate forANI Pharmaceuticals’ earnings has gone up from $3.31 per share to $3.73 for 2023. The bottom-line estimate has increased from $4.32 to $4.35 for 2024 during the same time frame. Shares of the company have rallied 60.6% year to date.
ANIP’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 91.56%.
In the past 90 days, the Zacks Consensus Estimate for Annovis Bio has narrowed from a loss of $4.89 per share to a loss of $4.38 for 2023. The bottom-line estimate has narrowed from a loss of $3.18 to $2.77 for 2024 during the same time frame. Shares of the company have lost 7.9% year to date.
ANVS’ earnings beat estimates in three of the trailing four quarters and missed the mark in one, delivering an average surprise of 13.40%.
In the past 90 days, the Zacks Consensus Estimate for Corcept’s earnings has gone up from 62 cents per share to 78 cents for 2023. The bottom-line estimate has also improved from 61 cents to 83 cents for 2024 during the same time frame. Shares of the company have rallied 61.8% year to date.
CORT’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 6.99%.